Ascelia Pharma AB (CHIX:ACES) Land And Improvements: kr0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ACES Ascelia Pharma AB CHIX:ACES
17 GF Score
Price kr3.29
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB Land And Improvements?

Ascelia Pharma AB CHIX:ACES 17 Land And Improvements is kr0.00 Mil as of Jun. 2026. GuruFocus rates CHIX:ACES with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Ascelia Pharma AB's land and improvements for the quarter that ended in Jun. 2026 was kr0.00 Mil.

Ascelia Pharma AB Land And Improvements Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB Land And Improvements Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Land And Improvements
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ascelia Pharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:ACES
17GF Score
Ascelia Pharma AB CHIX:ACES
Land And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Frequently Asked Questions Learn more about Land And Improvements →
What does a Land And Improvements of kr0.00 Mil mean?
Ascelia Pharma AB (CHIX:ACES) has a Land And Improvements of kr0.00 Mil as of Jun. 2026. Land and improvements records the total value of a company's land and improvements to it. View historical data on Ascelia Pharma AB and its competitors.
Is Ascelia Pharma AB's Land And Improvements too high?
Ascelia Pharma AB's current Land And Improvements is kr0.00 Mil. Overall, Ascelia Pharma AB has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's Land And Improvements compare to VRTX and REGN?
Ascelia Pharma AB's Land And Improvements of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Land And Improvements for a Biotechnology company?
A good Land And Improvements depends on the Biotechnology industry context. However, Land And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Land And Improvements mean?
A high Land And Improvements can signal that a stock is expensive relative to its fundamentals. Land and improvements records the total value of a company's land and improvements to it. View historical data on Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current Land And Improvements is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (CHIX:ACES) has a current Land And Improvements of kr0.00 Mil. The current Land And Improvements is kr0.00 Mil. Ascelia Pharma AB's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Land And Improvements calculated?
Land And Improvements is calculated from a company's financial statements. For Ascelia Pharma AB (CHIX:ACES), the current Land And Improvements is kr0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACE:Sweden
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a Swedish biopharmaceutical company focused on developing drugs for orphan oncology and supportive care. Its lead candidate, Orviglance (manganese chloride tetrahydrate), is an oral contrast agent for magnetic resonance imaging designed to improve detection and visualization of focal liver lesions, including liver metastases and primary tumors, particularly in patients with impaired kidney function who cannot receive standard gadolinium-based contrast agents. The company's other program, Oncoral, is an oral irinotecan tablet being developed as a more convenient alternative to intravenous irinotecan for certain cancer indications. Ascelia Pharma operates as a clinical-stage company, with development activities conducted in Sweden and other European markets, and its revenue model depends on licensing, partnership, or commercialization arrangements following regulatory approval rather than on marketed product sales.
17GF Score

Get the complete analysis for CHIX:ACES

Land And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.29
Price